Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Demant rises sharply after double upgrade by BofA

    The Demant share climbed about 3.5% today after BofA Securities raised its rating from "Underperform" to "Buy" and increased the price target from DKK 170 to DKK 280. BofA justified the upgrade with stronger market growth in the first quarter, improved demand for the Oticon Zeal product, raised EPS forecasts for 2026 and 2027, and lower capital costs. The revaluation pushed the stock toward the new price target and supports a recovery thesis for Demant. » More on de.investing.com


  • Demant exceeds Q1 revenue forecast thanks to Oticon Zeal and acquisitions

    Demant reports Q1 2026 revenue of USD 6.25 billion, 2.46% above the USD 6.1 billion forecast. Total growth was 16%, driven by 6% organic growth and 10% acquisition-driven growth (mainly from the acquisition of KIND); EPS met expectations. Strong sales in North America and Europe and the launch of Oticon Zeal lifted the gross margin, and the stock rose 0.97% after hours to USD 209.2. Management confirms the 2026 outlook and remains confident about further product launches in the second half of the year. » More on de.investing.com


  • Demant beats Q1 revenue forecast thanks to hearing-aid growth, stock jumps sharply

    Demant reported Q1 2026 revenue of USD 6.25 billion, exceeding the USD 6.1 billion forecast. Drivers were 6% organic growth and roughly 10% acquisition-driven growth following the integration of KIND, as well as the product launch of Oticon Seal, which led to an expansion of gross margin. The stock rose 10.9% to USD 232 after the announcement. Management confirmed the full-year guidance for organic growth of 3–6% and an EBIT range of DKK 4.1–4.5 billion, but cited currency risks and potential market saturation as challenges. » More on de.investing.com


  • William Demant falls 13% after quarterly results

    William Demant reported acquisition-driven revenue growth in Q4 2025, while EBIT before special items fell 10% and free cash flow declined 11%. The takeover of the KIND group increased net debt and pushed the leverage ratio to 3.4, prompting management to suspend share buybacks and prioritize debt reduction. Newly introduced premium hearing aid Oticon Seal is expected to drive growth but failed to reassure investors. For 2026 the company expects organic growth of 3–6% and an EBIT of DKK 4.1–4.5 billion; a return to the leverage target is planned within 18–24 months. » More on de.investing.com


  • Demant acquires Kind and becomes Germany's largest hearing-aid chain

    The Federal Cartel Office has approved the takeover of around 600 Kind branches by the Danish group Demant. Demant is also buying Audifon, the manufacturer owned by Kind, combining about 350 of its own branches in Germany with the acquired locations. The authority considers there to be sufficient competition from other chains, opticians and regional providers despite the merger. The Kind brand name is to be retained, and the previous owning family will withdraw after the transaction is completed. » More on spiegel.de

Historical dividends Dividends

All dividend metrics All metrics

In 2000, Demant has already paid €0.0802 in dividends. The last payout was in May 2000.

Financials

In the last quarter, Demant had revenue of €1.73B and net profit of €158.11M

(EUR) June 2026
YoY
Revenue 1.73B -
Gross profit 1.34B -
Net profit 158.11M -
EBITDA 413.66M -

Fundamentals

Metric Value
Market capitalization
€10.25B
Number of shares
210.9M
52-week high/low
€49.02 - €25.57
Dividends No
Beta
0.76
P/E ratio
44.72
PEG ratio
-1.54
P/B ratio
6.41
P/S ratio
2.93

Company profile

Demant A/S, a hearing healthcare and audio technology company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. It operates in two segments, Hearing Healthcare and Communications. The Hearing Healthcare segment offers hearing implants and aids, hearing care, and diagnostic products. The Communications segment provides headsets for collaborative work and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.

Name
Demant
CEO
Søren Nielsen
Headquarters Smørum, ze
Denmark
Website
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO
05/08/2000
Employees 26,704

Ticker symbols

Exchange Symbol
Pnk
WILLF
Nasdaq Copenhagen
DEMANT.CO
Copenhagen
DEMANT.CO
Frankfurt
WDH1.F
Düsseldorf
WDH1.DU
London
0RGT.L
SIX
WDH.SW
München
WDH1.MU
Wien
DEMA.VI
🍪

Parqet  uses cookies. Learn more